Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Lifecore Biomedical, Inc. (NASDAQ: LFCR), a specialized injectables contract development and manufacturing organization (CDMO), has announced its participation in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum taking place from March 17 to 18, 2026. The event is set to feature a fireside chat with Lifecore's management, where key insights and updates about the company's operations will be discussed.

Mr. Josephs, a prominent figure within the organization, will be presenting during the session scheduled for Tuesday, March 17, 2026, from 9:00 AM to 9:35 AM Eastern Time. This interactive fireside chat will be accessible via a webcast, which can be found on Lifecore’s investor relations website under the Investor Events & Presentations section. Additionally, a replay of the discussion will be made available post-conference for those unable to attend live.

Lifecore Biomedical is known for its comprehensive capabilities in creating and manufacturing sterile injectable pharmaceutical products, including complex formulations in various delivery formats such as syringes, vials, and cartridges. With over 40 years of experience, Lifecore has established itself as a leader in the development of premium, injectable-grade hyaluronic acid, and serves a diverse range of clients in the biopharmaceutical and biotechnology sectors. The company prides itself on its commitment to bringing innovative therapeutic solutions to market, supporting both established global brands and emerging industry players.

For more information about Lifecore and to keep updated on their initiatives, stakeholders can visit the company’s website at www.lifecore.com. Investors and media inquiries can be directed to Vida Strategic Partners or directly to Lifecore's CFO, Ryan D. Lake.

As Lifecore Biomedical (NASDAQ: LFCR) prepares to showcase its capabilities at the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum on March 17-18, 2026, investors should take note of several key dynamics influencing the company’s market position and potential.

Lifecore's unique standing as a fully integrated injectables contract development and manufacturing organization (CDMO) highlights its essential role in the biopharmaceutical industry. With over 40 years of expertise and a focus on complex formulations, Lifecore is well-positioned to capture growth opportunities within the rapidly expanding injectable drug market. The company's specialty in injectable-grade hyaluronic acid and diverse therapeutic applications enables it to attract global and emerging biopharmaceutical companies, thereby enhancing its revenue potential.

The upcoming fireside chat featuring Mr. Josephs is an opportunity for investors to gain insights into Lifecore’s strategic direction and operational advancements. As management engages with investors, look for updates regarding contract wins, partnerships, and project advancements that could catalyze growth. A successful presentation can boost investor confidence and potentially lead to positive market sentiment, impacting LFCR's stock price favorably.

In light of current market trends, it is advisable for investors to monitor Lifecore's performance closely, evaluating any insights or forward guidance provided during the conference. Additionally, keeping an eye on the broader CDMO market’s growth trajectory, driven by increasing demand for sterile injectables, will help in assessing Lifecore's relative strength.

Given its robust capabilities and industry experience, Lifecore Biomedical presents a compelling investment opportunity, especially if it continues to establish strategic partnerships and leverage its technical expertise. Engaging with management during the forum can provide valuable insights to inform investment decisions as the company navigates the evolving healthcare landscape.